Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
作者信息
Gautret Philippe, Hoang Van Thuan, Honoré Stéphane, Roussel Yanis, Million Matthieu, Lagier Jean-Christophe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106241. doi: 10.1016/j.ijantimicag.2020.106241.
Abstract
摘要
相似文献
1
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于治疗COVID-19患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106241. doi: 10.1016/j.ijantimicag.2020.106241.
2
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
3
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
4
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.羟氯喹、阿奇霉素和环索奈德三联疗法治疗 COVID-19 肺炎。
J Microbiol Immunol Infect. 2021 Feb;54(1):109-112. doi: 10.1016/j.jmii.2020.09.003. Epub 2020 Oct 5.
5
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.羟氯喹啉联合或不联合阿奇霉素对COVID-19患者死亡率的影响：作者回应
Clin Microbiol Infect. 2021 Jan;27(1):138-140. doi: 10.1016/j.cmi.2020.10.002. Epub 2020 Oct 17.
6
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量的影响尚不确定。
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
7
Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒清除的影响：对埃尔韦·塞利格曼的回应
Int J Antimicrob Agents. 2021 Mar;57(3):106306. doi: 10.1016/j.ijantimicag.2021.106306. Epub 2021 Feb 14.
8
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
9
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
10
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
引用本文的文献
1
One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview.巴西的 2019 冠状病毒病（COVID-19）一年：政治和社会概述。
Ann Glob Health. 2021 May 18;87(1):44. doi: 10.5334/aogh.3182.
2
[COVID-19 and medical publications: How three articles have influenced the media and public decisions in France].[新冠疫情与医学出版物：三篇文章如何影响了法国的媒体和公众决策]
Rev Med Interne. 2021 Aug;42(8):583-590. doi: 10.1016/j.revmed.2021.03.010. Epub 2021 Mar 23.
本文引用的文献
1
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.羟氯喹和阿奇霉素治疗COVID-19的效果：一项开放标签非随机临床试验的结果，意向性分析及临床结局的更新
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
2
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
3
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
4
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world.氯喹衍生物在新型冠状病毒肺炎感染中的临床疗效：大数据与真实世界的比较荟萃分析
New Microbes New Infect. 2020 Jun 6;38:100709. doi: 10.1016/j.nmni.2020.100709. eCollection 2020 Nov.
5
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.法国马赛接受羟氯喹/阿奇霉素和其他方案治疗的 3737 例 COVID-19 患者的结局：一项回顾性分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
Zotero 插件